Ronald J Ellis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9542054/publications.pdf

Version: 2024-02-01

379 papers 25,811 citations

76 h-index 145 g-index

388 all docs 388 docs citations

times ranked

388

12451 citing authors

#	Article	IF	CITATIONS
1	HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy. Neurology, 2010, 75, 2087-2096.	1.5	2,036
2	HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of NeuroVirology, 2011, 17, 3-16.	1.0	1,327
3	Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System. Archives of Neurology, 2008, 65, 65.	4.9	777
4	The impact of HIV-associated neuropsychological impairment on everyday functioning. Journal of the International Neuropsychological Society, 2004, 10, 317-31.	1.2	653
5	The HNRC 500-Neuropsychology of Hiv infection at different disease stages. Journal of the International Neuropsychological Society, 1995, 1, 231-251.	1.2	605
6	The prevalence and incidence of neurocognitive impairment in the HAART era. Aids, 2007, 21, 1915-1921.	1.0	539
7	Dendritic injury is a pathological substrate for human immunodeficiency virus?related cognitive disorders. Annals of Neurology, 1997, 42, 963-972.	2.8	463
8	HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nature Reviews Neuroscience, 2007, 8, 33-44.	4.9	458
9	Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial. Neuropsychopharmacology, 2009, 34, 672-680.	2.8	392
10	Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. Journal of the International Neuropsychological Society, 2004, 10, 1-14.	1.2	380
11	Continued High Prevalence and Adverse Clinical Impact of Human Immunodeficiency Virus–Associated Sensory Neuropathy in the Era of Combination Antiretroviral Therapy. Archives of Neurology, 2010, 67, 552.	4.9	347
12	CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. Aids, 2011, 25, 1747-1751.	1.0	345
13	Neurocognitive Change in the Era of HIV Combination Antiretroviral Therapy: The Longitudinal CHARTER Study. Clinical Infectious Diseases, 2015, 60, 473-480.	2.9	326
14	Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Annals of Neurology, 1997, 42, 679-688.	2.8	314
15	Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. Aids, 2009, 23, 1359-1366.	1.0	305
16	Soluble CD163 Made by Monocyte/Macrophages Is a Novel Marker of HIV Activity in Early and Chronic Infection Prior to and After Anti-retroviral Therapy. Journal of Infectious Diseases, 2011, 204, 154-163.	1.9	286
17	Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology, 2009, 73, 342-348.	1.5	268
18	Co-Morbidities in Persons Infected with HIV: Increased Burden with Older Age and Negative Effects on Health-Related Quality of Life. AIDS Patient Care and STDs, 2013, 27, 5-16.	1.1	267

#	Article	IF	CITATIONS
19	Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology, 2014, 82, 2055-2062.	1.5	255
20	Effects of Methamphetamine Dependence and HIV Infection on Cerebral Morphology. American Journal of Psychiatry, 2005, 162, 1461-1472.	4.0	249
21	Dementia and Neurocognitive Disorders Due to HIV-1 Infection. Seminars in Neurology, 2007, 27, 086-092.	0.5	249
22	Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. Aids, 2013, 27, 1387-1395.	1.0	235
23	Circuit party attendance, club drug use, and unsafe sex in gay men. Journal of Substance Abuse, 2001, 13, 119-126.	1.1	221
24	Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Annals of Neurology, 2004, 56, 416-423.	2.8	215
25	Neurocognitive Impairment Is an Independent Risk Factor for Death in HIV Infection. Archives of Neurology, 1997, 54, 416-424.	4.9	207
26	Increased Human Immunodeficiency Virus Loads in Active Methamphetamine Users Are Explained by Reduced Effectiveness of Antiretroviral Therapy. Journal of Infectious Diseases, 2003, 188, 1820-1826.	1.9	201
27	Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis ofÂlndividual Patient Data. Journal of Pain, 2015, 16, 1221-1232.	0.7	198
28	Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology, 2000, 54, 927-936.	1.5	193
29	Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. Aids, 2006, 20, 879-887.	1.0	192
30	Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. Aids, 2011, 25, 357-365.	1.0	190
31	Progressive Cerebral Volume Loss in Human Immunodeficiency Virus Infection. Archives of Neurology, 1998, 55, 161.	4.9	176
32	Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. Journal of NeuroVirology, 2009, 15, 360-370.	1.0	176
33	Peripheral neuropathy in HIV: prevalence and risk factors. Aids, 2011, 25, 919-928.	1.0	171
34	Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology, 2012, 78, 485-492.	1.5	168
35	Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology, 2013, 80, 1415-1423.	1.5	160
36	Brain mitochondrial injury in human immunodeficiency virus–seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. Journal of NeuroVirology, 2005, 11, 356-364.	1.0	158

#	Article	IF	CITATIONS
37	Clinical factors related to brain structure in HIV: the CHARTER study. Journal of NeuroVirology, 2011, 17, 248-57.	1.0	158
38	Action (verb) fluency: Test–retest reliability, normative standards, and construct validity. Journal of the International Neuropsychological Society, 2005, 11, 408-415.	1.2	156
39	Progression to Neuropsychological Impairment in Human Immunodeficiency Virus Infection Predicted by Elevated Cerebrospinal Fluid Levels of Human Immunodeficiency Virus RNA. Archives of Neurology, 2002, 59, 923.	4.9	149
40	Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Annals of Neurology, 2008, 64, 566-572.	2.8	147
41	HIV Infection and Aging Independently Affect Brain Function as Measured by Functional Magnetic Resonance Imaging. Journal of Infectious Diseases, 2010, 201, 336-340.	1.9	145
42	Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 505-522.	0.8	143
43	Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. Aids, 2002, 16, 1019-1029.	1.0	141
44	Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. Aids, 2007, 21, 1877-1886.	1.0	141
45	Alcoholism, aging, and functional cerebral asymmetries Psychological Bulletin, 1989, 106, 128-147.	5.5	138
46	Neurologic complications of HIV disease and their treatment. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2010, 18, 45-55.	2.9	138
47	Genetic Composition of Human Immunodeficiency Virus Type 1 in Cerebrospinal Fluid and Blood without Treatment and during Failing Antiretroviral Therapy. Journal of Virology, 2005, 79, 1772-1788.	1.5	136
48	White matter tract injury and cognitive impairment in human immunodeficiency virus–infected individuals. Journal of NeuroVirology, 2009, 15, 187-195.	1.0	131
49	Pathogenesis of Hepatitis C Virus Coinfection in the Brains of Patients Infected with HIV. Journal of Infectious Diseases, 2007, 196, 361-370.	1.9	125
50	Resting cerebral blood flow. Neurology, 2009, 73, 702-708.	1.5	120
51	Prospective Memory in HIV-1 Infection. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 536-548.	0.8	119
52	Timing is everything: Antiretroviral nonadherence is associated with impairment in time-based prospective memory. Journal of the International Neuropsychological Society, 2009, 15, 42-52.	1.2	119
53	Synergistic Effects of HIV Infection and Older Age on Daily Functioning. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 341-348.	0.9	116
54	Patterns of Selective Neuronal Damage in Methamphetamine-User AIDS Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 467-474.	0.9	115

#	Article	IF	CITATIONS
55	The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. Aids, 2005, 19, S72-S78.	1.0	114
56	Low atazanavir concentrations in cerebrospinal fluid. Aids, 2009, 23, 83-87.	1.0	112
57	Deficient Strategic Control of Verbal Encoding and Retrieval in Individuals With Methamphetamine Dependence Neuropsychology, 2005, 19, 35-43.	1.0	111
58	Correlation of In Vivo Neuroimaging Abnormalities With Postmortem Human Immunodeficiency Virus Encephalitis and Dendritic Loss. Archives of Neurology, 2004, 61, 369.	4.9	110
59	Randomized Trial of Central Nervous System–Targeted Antiretrovirals for HIV-Associated Neurocognitive Disorder. Clinical Infectious Diseases, 2014, 58, 1015-1022.	2.9	110
60	Variable patterns of neuropsychological performance in HIV-1 infection. Journal of Clinical and Experimental Neuropsychology, 2008, 30, 613-626.	0.8	103
61	Psychometric Characteristics of the Memory for Intentions Screening Test. Clinical Neuropsychologist, 2008, 22, 864-878.	1.5	101
62	Effects of HIV-1 infection and aging on neurobehavioral functioning. Aids, 2004, 18, 27-34.	1.0	100
63	Neuropsychological deficits in human immunodeficiency virus type 1 clade C–seropositive adults from South India. Journal of NeuroVirology, 2007, 13, 195-202.	1.0	100
64	Two-year prospective study of major depressive disorder in HIV-infected men. Journal of Affective Disorders, 2008, 108, 225-234.	2.0	97
65	Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain, 2006, 129, 1872-1883.	3.7	94
66	Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. Aids, 2009, 23, 907-915.	1.0	94
67	Hepatitis C virus infection is associated with reduced white matter N-acetylaspartate in abstinent methamphetamine users. Journal of the International Neuropsychological Society, 2004, 10, 110-3.	1,2	90
68	Lithium improves HIV-associated neurocognitive impairment. Aids, 2006, 20, 1885-1888.	1.0	89
69	HIV Infection and the Central Nervous System: A Primer. Neuropsychology Review, 2009, 19, 144-151.	2.5	88
70	Regional patterns of brain metabolites in AIDS dementia complex. NeuroImage, 2004, 23, 928-935.	2.1	87
71	Altered P-Glycoprotein Expression in AIDS Patients with HIV Encephalitis. Journal of Neuropathology and Experimental Neurology, 2004, 63, 1038-1047.	0.9	84
72	Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2012, 24, 1504-1513.	0.6	83

#	Article	IF	CITATIONS
73	A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology, 2007, 69, 1314-1321.	1.5	82
74	Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. Journal of Antimicrobial Chemotherapy, 2011, 66, 354-357.	1.3	82
75	Extrapyramidal Motor Signs in Clinically Diagnosed Alzheimer Disease. Alzheimer Disease and Associated Disorders, 1996, 10, 103-114.	0.6	79
76	Incidence of Post-Dural Puncture Headache in Research Volunteers. Headache, 2011, 51, 1503-1510.	1.8	79
77	Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. Journal of NeuroVirology, 2011, 17, 63-69.	1.0	79
78	HIV alters neuronal mitochondrial fission/fusion in the brain during HIV-associated neurocognitive disorders. Neurobiology of Disease, 2016, 86, 154-169.	2.1	79
79	White matter damage, neuroinflammation, and neuronal integrity in HAND. Journal of NeuroVirology, 2019, 25, 32-41.	1.0	77
80	Proton MRS and Neuropsychological Correlates in AIDS Dementia Complex: Evidence of Subcortical Specificity. Journal of Neuropsychiatry and Clinical Neurosciences, 2007, 19, 283-292.	0.9	75
81	HIV protease inhibitor exposure predicts cerebral small vessel disease. Aids, 2014, 28, 1297-1306.	1.0	75
82	Minocycline treatment for HIV-associated cognitive impairment. Neurology, 2011, 77, 1135-1142.	1.5	74
83	HIV Infection Is Associated with Attenuated Frontostriatal Intrinsic Connectivity: A Preliminary Study. Journal of the International Neuropsychological Society, 2015, 21, 203-213.	1.2	74
84	Abdominal Obesity Contributes to Neurocognitive Impairment in HIV-Infected Patients With Increased Inflammation and Immune Activation. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 281-288.	0.9	73
85	Low Cerebrospinal Fluid Concentrations of the Nucleotide HIV Reverse Transcriptase Inhibitor, Tenofovir. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 376-381.	0.9	72
86	Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. Journal of NeuroVirology, 2013, 19, 65-74.	1.0	72
87	Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus–infected patients. Journal of NeuroVirology, 2006, 12, 100-107.	1.0	70
88	HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. Aids, 2007, 21, 1109-1117.	1.0	69
89	Neuropathologic confirmation of definitional criteria for human immunodeficiency virus–associated neurocognitive disorders. Journal of NeuroVirology, 2007, 13, 23-28.	1.0	69
90	A neuropsychological investigation of multitasking in HIV infection: Implications for everyday functioning Neuropsychology, 2011, 25, 511-519.	1.0	69

#	Article	IF	CITATIONS
91	A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain Research, 2012, 1431, 46-52.	1.1	69
92	Diagnostic Validity of the Dementia Questionnaire for Alzheimer Disease. Archives of Neurology, 1998, 55, 360.	4.9	67
93	Visual Attention Deficits are Associated with Driving Accidents in Cognitively-Impaired HIV-Infected Individuals. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 13-28.	0.8	67
94	Implications of Apathy for Everyday Functioning Outcomes in Persons Living with HIV Infection. Archives of Clinical Neuropsychology, 2012, 27, 520-531.	0.3	67
95	Association Between Frailty and Components of the Frailty Phenotype With Modifiable Risk Factors and Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 933-937.	1.9	67
96	Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 105-113.	1.9	67
97	Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. Aids, 2004, 18 Suppl 1, S27-34.	1.0	67
98	Clinical validation of the NeuroScreen. Journal of NeuroVirology, 2005, 11, 503-511.	1.0	65
99	The impact of neuropsychological functioning and depressed mood on functional complaints in HIV-1 infection and methamphetamine dependence. Journal of Clinical and Experimental Neuropsychology, 2007, 29, 266-276.	0.8	65
100	The Veterans Aging Cohort Study Index is Associated With Concurrent Risk for Neurocognitive Impairment. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 190-197.	0.9	65
101	Cerebrospinal Fluid (CSF) CD8+ T-Cells That Express Interferon-Gamma Contribute to HIV Associated Neurocognitive Disorders (HAND). PLoS ONE, 2015, 10, e0116526.	1.1	65
102	Physical exercise is associated with less neurocognitive impairment among HIV-infected adults. Journal of NeuroVirology, 2013, 19, 410-417.	1.0	64
103	Prediction of Incident Neurocognitive Impairment by Plasma HIV RNA and CD4 Levels Early After HIV Seroconversion. Archives of Neurology, 2003, 60, 1406.	4.9	63
104	Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1. Antimicrobial Agents and Chemotherapy, 2010, 54, 5156-5160.	1.4	63
105	A battery approach for measuring neuropsychological change. Archives of Clinical Neuropsychology, 2006, 21, 83-89.	0.3	62
106	HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon. BMC Neurology, 2010, 10, 60.	0.8	62
107	CNS Neurotoxicity of Antiretrovirals. Journal of NeuroImmune Pharmacology, 2021, 16, 130-143.	2.1	58
108	Memantine for AIDS Dementia Complex: Open-Label Report of ACTG 301. HIV Clinical Trials, 2010, 11, 59-67.	2.0	57

#	Article	IF	CITATIONS
109	Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. Journal of NeuroVirology, 2013, 19, 150-156.	1.0	57
110	Types of Cerebrovascular Lesions Associated with Severe Cerebral Amyloid Angiopathy in Alzheimer's Disease. Annals of the New York Academy of Sciences, 1997, 826, 493-497.	1.8	55
111	Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. Journal of Neuroimmunology, 2005, 169, 144-152.	1.1	55
112	Human Immunodeficiency Virus Infection Heightens Concurrent Risk of Functional Dependence in Persons With Long-Term Methamphetamine Use. Journal of Addiction Medicine, 2013, 7, 255-263.	1.4	55
113	AIDS-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy. Aids, 2001, 15, 1898-1899.	1.0	53
114	Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1–Infected Adults in the United States. Clinical Infectious Diseases, 2018, 67, 1182-1190.	2.9	52
115	Early Antiretroviral Therapy Is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations. PLoS Pathogens, 2017, 13, e1006112.	2.1	52
116	Osteopontin Is Increased in HIVâ€Associated Dementia. Journal of Infectious Diseases, 2008, 198, 715-722.	1.9	51
117	Computerized reaction time battery versus a traditional neuropsychological battery: Detecting HIV-related impairments. Journal of the International Neuropsychological Society, 2003, 9, 64-71.	1.2	50
118	Population Pharmacokinetics of Abacavir in Plasma and Cerebrospinal Fluid. Antimicrobial Agents and Chemotherapy, 2005, 49, 2504-2506.	1.4	50
119	Neurocognitive impairment in HIV-1 clade C- versus B-infected individuals in Southern Brazil. Journal of NeuroVirology, 2013, 19, 550-556.	1.0	50
120	Sex differences in HIV-associated cognitive impairment. Aids, 2018, 32, 2719-2726.	1.0	50
121	Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. Journal of Clinical and Experimental Neuropsychology, 2008, 30, 83-90.	0.8	49
122	Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy. Virus Evolution, 2016, 2, vew020.	2.2	49
123	Indinavir Population Pharmacokinetics in Plasma and Cerebrospinal Fluid. Antimicrobial Agents and Chemotherapy, 2000, 44, 2173-2175.	1.4	47
124	Retrograde Amnesia in Dementia: Comparison of HIV-Associated Dementia, Alzheimer's Disease, and Huntington's Disease Neuropsychology, 2004, 18, 692-699.	1.0	47
125	Test–retest stability of calibrated BOLD-fMRI in HIVâ^' and HIV+ subjects. NeuroImage, 2011, 54, 2156-2162.	2.1	47
126	CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults. Journal of Neuroimmunology, 2004, 157, 185-192.	1.1	45

#	Article	IF	Citations
127	HIV-Infected Individuals with Co-occurring Bipolar Disorder Evidence Poor Antiretroviral and Psychiatric Medication Adherence. AIDS and Behavior, 2012, 16, 2257-2266.	1.4	45
128	Peripheral neuropathy in ART-experienced patients: prevalence and risk factors. Journal of NeuroVirology, 2013, 19, 557-564.	1.0	45
129	Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy. Aids, 2019, 33, 475-481.	1.0	44
130	Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders. International Review of Psychiatry, 2008, 20, 89-93.	1.4	43
131	HIV and Aging: Effects on the Central Nervous System. Seminars in Neurology, 2014, 34, 027-034.	0.5	43
132	Cannabis Exposure is Associated With a Lower Likelihood of Neurocognitive Impairment in People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 56-64.	0.9	43
133	Implications of apathy and depression for everyday functioning in HIV/AIDS in Brazil. Journal of Affective Disorders, 2013, 150, 1069-1075.	2.0	42
134	Apathy is associated with white matter abnormalities in anterior, medial brain regions in persons with HIV infection. Journal of Clinical and Experimental Neuropsychology, 2014, 36, 854-866.	0.8	42
135	Tryptophan Metabolism and Its Relationship with Depression and Cognitive Impairment among HIV-infected Individuals. International Journal of Tryptophan Research, 2016, 9, IJTR.S36464.	1.0	42
136	Frailty, Neurocognitive Impairment, or Both in Predicting Poor Health Outcomes Among Adults Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2019, 68, 131-138.	2.9	42
137	Cognitive Deficits Related to Memory Impairments in Alcoholism. Recent Developments in Alcoholism: an Official Publication of the American Medical Society on Alcoholism, and the Research Society on Alcoholism, and the National Council on Alcoholism, 1987, 5, 59-80.	0.4	42
138	Neurologic complications of HIV disease and their treatment. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2009, 17, 46-56.	2.9	42
139	Clinical features and preliminary studies of virological correlates of neurocognitive impairment among HIV-infected individuals in Nigeria. Journal of NeuroVirology, 2012, 18, 191-199.	1.0	41
140	Early-onset Alzheimer's disease with a presenilin-1 mutation at the site corresponding to the volga German presenilin-2 mutation. Annals of Neurology, 1997, 42, 124-128.	2.8	40
141	Lopinavir with Ritonavir Reduces the HIV RNA Level in Cerebrospinal Fluid. Clinical Infectious Diseases, 2007, 45, 1511-1517.	2.9	40
142	Neurocognitive functioning in acute or early HIV infection. Journal of NeuroVirology, 2011, 17, 50-57.	1.0	40
143	Health-Related Quality of Life †Well-Being' in HIV Distal Neuropathic Pain is More Strongly Associated with Depression Severity than with Pain Intensity. Psychosomatics, 2012, 53, 380-386.	2.5	40
144	Can research at the end of life be a useful tool to advance HIV cure?. Aids, 2017, 31, 1-4.	1.0	39

#	Article	IF	CITATIONS
145	The monocyte chemotactic protein-1 -2578C allele is associated with elevated MCP-1 concentrations in cerebrospinal fluid. Journal of Neuroimmunology, 2004, 157, 193-196.	1.1	38
146	The Role of Cohort Studies in Drug Development: Clinical Evidence of Antiviral Activity of Serotonin Reuptake Inhibitors and HMG-CoA Reductase Inhibitors in the Central Nervous System. Journal of NeuroImmune Pharmacology, 2007, 2, 120-127.	2.1	38
147	Cognitive mechanisms of switching in HIV-associated category fluency deficits. Journal of Clinical and Experimental Neuropsychology, 2008, 30, 797-804.	0.8	38
148	Association of self-reported painful symptoms with clinical and neurophysiologic signs in HIV-associated sensory neuropathy. Pain, 2010, 151, 732-736.	2.0	38
149	Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. Journal of NeuroVirology, 2013, 19, 393-401.	1.0	38
150	Temperament and risky behaviors: a pathway to HIV?. Journal of Affective Disorders, 2005, 85, 191-200.	2.0	37
151	"Frontal systems―behaviors in comorbid human immunodeficiency virus infection and methamphetamine dependency. Psychiatry Research, 2014, 215, 208-216.	1.7	37
152	Cognitive deficits associated with combined HIV gp120 expression and chronic methamphetamine exposure in mice. European Neuropsychopharmacology, 2015, 25, 141-150.	0.3	37
153	Stroke incidence is highest in women and non-Hispanic blacks living with HIV in the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort. Aids, 2018, 32, 1125-1135.	1.0	37
154	Screening for major depression in persons with HIV infection: the concurrent predictive validity of the Profile of Mood States Depression-Dejection Scale. International Journal of Methods in Psychiatric Research, 2006, 15, 75-82.	1.1	36
155	Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings. Journal of NeuroVirology, 2011, 17, 239-247.	1.0	35
156	HIV and Chronic Methamphetamine Dependence Affect Cerebral Blood Flow. Journal of NeuroImmune Pharmacology, 2011, 6, 409-419.	2.1	35
157	The Cerebrospinal Fluid HIV Risk Score for Assessing Central Nervous System Activity in Persons With HIV. American Journal of Epidemiology, 2014, 180, 297-307.	1.6	35
158	$(1\hat{a}\dagger'3)$ - \hat{l}^2 -D-Glucan Levels Correlate With Neurocognitive Functioning in HIV-Infected Persons on Suppressive Antiretroviral Therapy. Medicine (United States), 2016, 95, e3162.	0.4	35
159	Effects of comorbidity burden and age on brain integrity in HIV. Aids, 2019, 33, 1175-1185.	1.0	35
160	Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. Neuroscience Letters, 1998, 254, 1-4.	1.0	34
161	Characterization of Interference with 6 Commercial î"9-Tetrahydrocannabinol Immunoassays by Efavirenz (Glucuronide) in Urine. Clinical Chemistry, 2006, 52, 896-897.	1.5	34
162	Cerebrospinal fluid human immunodeficiency virus viral load in patients with neurosyphilis. Journal of NeuroVirology, 2010, 16, 6-12.	1.0	34

#	Article	IF	Citations
163	Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. Journal of Antimicrobial Chemotherapy, 2013, 68, 684-689.	1.3	34
164	A Longitudinal Analysis of the Impact of Physical Activity on Neurocognitive Functioning Among HIV-Infected Adults. AIDS and Behavior, 2018, 22, 1562-1572.	1.4	34
165	Different roles of frontal versus striatal atrophy in HIVâ€associated neurocognitive disorders. Human Brain Mapping, 2019, 40, 3010-3026.	1.9	34
166	Antiretroviral drug concentrations in brain tissue of adult decedents. Aids, 2020, 34, 1907-1914.	1.0	34
167	Neurotoxic effects of the HCV core protein are mediated by sustained activation of ERK via TLR2 signaling. Journal of NeuroVirology, 2011, 17, 327-340.	1.0	33
168	NGX-4010, a Capsaicin 8% Dermal Patch, for the Treatment of Painful HIV-associated Distal Sensory Polyneuropathy. Clinical Journal of Pain, 2014, 30, 134-142.	0.8	33
169	Disability Among Middle-Aged and Older Persons With Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2017, 65, 83-91.	2.9	33
170	Cerebrospinal Fluid Proteomics Reveals Potential Pathogenic Changes in the Brains of SIV-Infected Monkeys. Journal of Proteome Research, 2009, 8, 2253-2260.	1.8	32
171	Dopamine and its receptors play a role in the modulation of CCR5 expression in innate immune cells following exposure to Methamphetamine: Implications to HIV infection. PLoS ONE, 2018, 13, e0199861.	1.1	32
172	Recent cannabis use in HIV is associated with reduced inflammatory markers in CSF and blood. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	32
173	Effect of methamphetamine dependence on inhibitory deficits in a novel human open-field paradigm. Psychopharmacology, 2011, 215, 697-707.	1.5	31
174	Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy. Pain, 2015, 156, 731-739.	2.0	31
175	Health-Related Everyday Functioning in the Internet Age: HIV-Associated Neurocognitive Disorders Disrupt Online Pharmacy and Health Chart Navigation Skills. Archives of Clinical Neuropsychology, 2016, 31, acv090.	0.3	31
176	Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. Journal of Infectious Diseases, 2016, 213, 1065-1073.	1.9	31
177	Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection. Journal of NeuroVirology, 2016, 22, 191-200.	1.0	31
178	Association of antiretroviral therapy with brain aging changes among HIV-infected adults. Aids, 2018, 32, 2005-2015.	1.0	31
179	Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment: Open-Label Report of ACTG 5090. HIV Clinical Trials, 2007, 8, 437-446.	2.0	30
180	Impairments in fine-motor coordination and speed of information processing predict declines in everyday functioning in hepatitis C infection. Journal of Clinical and Experimental Neuropsychology, 2008, 30, 805-815.	0.8	30

#	Article	IF	CITATIONS
181	Are Time- and Event-based Prospective Memory Comparably Affected in HIV Infection?. Archives of Clinical Neuropsychology, 2011, 26, 250-259.	0.3	30
182	Misremembering Future Intentions in Methamphetamine-Dependent Individuals. Clinical Neuropsychologist, 2011, 25, 269-286.	1.5	30
183	Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment. Journal of Neuroinflammation, 2017, 14, 72.	3.1	30
184	HIV in the cART era and the mitochondrial: immune interface in the CNS. International Review of Neurobiology, 2019, 145, 29-65.	0.9	30
185	Pleocytosis is associated with disruption of HIV compartmentalization between blood and cerebral spinal fluid viral populations. Virology, 2009, 385, 204-208.	1.1	29
186	Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy. Aids, 2011, 25, F1-F6.	1.0	29
187	Genetic Variation in Iron Metabolism Is Associated with Neuropathic Pain and Pain Severity in HIV-Infected Patients on Antiretroviral Therapy. PLoS ONE, 2014, 9, e103123.	1.1	29
188	Antiretroviral therapy reduces neurodegeneration in HIV infection. Aids, 2015, 29, 323-330.	1.0	29
189	Mitochondrial biogenesis is altered in HIV+ brains exposed to ART: Implications for therapeutic targeting of astroglia. Neurobiology of Disease, 2019, 130, 104502.	2.1	29
190	Biomarkers of chemotaxis and inflammation in cerebrospinal fluid and serum in individuals with HIV-1 subtype C versus B. Journal of NeuroVirology, 2016, 22, 715-724.	1.0	28
191	Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates. Journal of the International Neuropsychological Society, 2019, 25, 507-519.	1.2	28
192	HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter. Journal of NeuroVirology, 2014, 20, 209-218.	1.0	27
193	Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection. Clinical Infectious Diseases, 2015, 61, 1476-1484.	2.9	27
194	The Veterans Aging Cohort Study (VACS) Index and Neurocognitive Change: A Longitudinal Study. Clinical Infectious Diseases, 2016, 63, 694-702.	2.9	27
195	Role of metabolic syndrome components in HIV-associated sensory neuropathy. Aids, 2009, 23, 2317-2322.	1.0	26
196	Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. Journal of NeuroVirology, 2016, 22, 479-487.	1.0	26
197	Genomeâ€wide association study of HIVâ€associated neurocognitive disorder (HAND): A CHARTER group study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 413-426.	1.1	26
198	Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen. Aids, 2017, 31, 1565-1571.	1.0	26

#	Article	IF	CITATIONS
199	Tenofovir disoproxil fumarate induces peripheral neuropathy and alters inflammation and mitochondrial biogenesis in the brains of mice. Scientific Reports, 2019, 9, 17158.	1.6	26
200	Altered Functional Response to Risky Choice in HIV Infection. PLoS ONE, 2014, 9, e111583.	1.1	26
201	Opioid blockade improves human recognition memory following physiological arousal. Pharmacology Biochemistry and Behavior, 2001, 70, 77-84.	1.3	25
202	Etravirine in CSF is highly protein bound. Journal of Antimicrobial Chemotherapy, 2013, 68, 1161-1168.	1.3	25
203	Neurocognitive functioning in a Romanian cohort of young adults with parenterally-acquired HIV-infection during childhood. Journal of NeuroVirology, 2014, 20, 496-504.	1.0	25
204	The impact of ethnicity/race on the association between the Veterans Aging Cohort Study (VACS) Index and neurocognitive function among HIV-infected persons. Journal of NeuroVirology, 2016, 22, 442-454.	1.0	25
205	Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining "symptomatic―versus "asymptomatic―HAND. Journal of NeuroVirology, 2017, 23, 67-	7 <mark>8</mark> .0	25
206	Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. Journal of NeuroVirology, 2012, 18, 511-520.	1.0	24
207	Concurrent Classification Accuracy of the HIV Dementia Scale for HIV-Associated Neurocognitive Disorders in the CHARTER Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 36-42.	0.9	24
208	Blood-CSF barrier and compartmentalization of CNS cellular immune response in HIV infection. Journal of Neuroimmunology, 2016, 301, 41-48.	1.1	24
209	Effects of HIV Infection, methamphetamine dependence and age on cortical thickness, area and volume. NeuroImage: Clinical, 2018, 20, 1044-1052.	1.4	24
210	Plasma (1 â†' 3)-β-d-glucan and suPAR levels correlate with neurocognitive performance in people living with HIV on antiretroviral therapy: a CHARTER analysis. Journal of NeuroVirology, 2019, 25, 837-843.	1.0	24
211	Inflammation Relates to Poorer Complex Motor Performance Among Adults Living With HIV on Suppressive Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 15-23.	0.9	24
212	Lower CSF homovanillic acid relates to higher burden of neuroinflammation and depression in people with HIV disease. Brain, Behavior, and Immunity, 2020, 90, 353-363.	2.0	23
213	Comparative Analysis of Cell-Associated HIV DNA Levels in Cerebrospinal Fluid and Peripheral Blood by Droplet Digital PCR. PLoS ONE, 2015, 10, e0139510.	1.1	22
214	Plasma soluble CD163 is associated with postmortem brain pathology in human immunodeficiency virus infection. Aids, 2017, 31, 973-979.	1.0	22
215	Neurocognitive functioning predicts frailty index in HIV. Neurology, 2018, 91, e162-e170.	1.5	22
216	Longitudinal evaluation of <scp>neurologicâ€post</scp> acute sequelae <scp>SARSâ€CoV</scp> â€2 infection symptoms. Annals of Clinical and Translational Neurology, 2022, 9, 995-1010.	1.7	22

#	Article	IF	CITATIONS
217	Expression of mannose binding lectin in HIV-1-infected brain: implications for HIV-related neuronal damage and neuroAIDS. Neurobehavioral HIV Medicine, 2011, 3, 41.	2.0	21
218	Cerebrospinal fluid (CSF) biomarkers of iron status are associated with CSF viral load, antiretroviral therapy, and demographic factors in HIV-infected adults. Fluids and Barriers of the CNS, 2017, 14, 11.	2.4	21
219	Effect of Cannabis Use on Human Immunodeficiency Virus DNA During Suppressive Antiretroviral Therapy. Clinical Infectious Diseases, 2020, 70, 140-143.	2.9	21
220	Improving Detection of HIV-Associated Cognitive Impairment: Comparison of the International HIV Dementia Scale and a Brief Screening Battery. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 332-338.	0.9	20
221	Frailty in medically complex individuals with chronic HIV. Aids, 2019, 33, 1603-1611.	1.0	20
222	Beneficial Effects of Cannabis on Blood–Brain Barrier Function in Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 73, 124-129.	2.9	20
223	Dichotic Asymmetries in Aging and Alcoholic Subjects. Alcoholism: Clinical and Experimental Research, 1990, 14, 863-871.	1.4	19
224	Estimating selection pressures on HIVâ€1 using phylogenetic likelihood models. Statistics in Medicine, 2008, 27, 4779-4789.	0.8	19
225	Plasma Proteomic Profiling in HIV-1 Infected Methamphetamine Abusers. PLoS ONE, 2012, 7, e31031.	1.1	19
226	Circulating HIV DNA Correlates With Neurocognitive Impairment in Older HIV-infected Adults on Suppressive ART. Scientific Reports, 2015, 5, 17094.	1.6	19
227	Coagulation imbalance and neurocognitive functioning in older HIV-positive adults on suppressive antiretroviral therapy. Aids, 2017, 31, 787-795.	1.0	19
228	Daily Cannabis Use is Associated With Lower CNS Inflammation in People With HIV. Journal of the International Neuropsychological Society, 2021, 27, 661-672.	1.2	19
229	Cognitive and Neuronal Link With Inflammation: A Longitudinal Study in People With and Without HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 617-625.	0.9	19
230	Role of metabolic syndrome components in human immunodeficiency virus–associated stroke. Journal of NeuroVirology, 2009, 15, 249-256.	1.0	18
231	Latent <i>Toxoplasma</i> Infection and Higher <i>Toxoplasma gondii</i> Immunoglobulin G Levels Are Associated With Worse Neurocognitive Functioning in HIV-Infected Adults. Clinical Infectious Diseases, 2016, 63, 1655-1660.	2.9	18
232	Increased cell-free mitochondrial DNA is a marker of ongoing inflammation and better neurocognitive function in virologically suppressed HIV-infected individuals. Journal of NeuroVirology, 2017, 23, 283-289.	1.0	18
233	HIV, prospective memory, and cerebrospinal fluid concentrations of quinolinic acid and phosphorylated Tau. Journal of Neuroimmunology, 2018, 319, 13-18.	1.1	18
234	Low CD4 nadir linked to widespread cortical thinning in adults living with HIV. NeuroImage: Clinical, 2020, 25, 102155.	1.4	18

#	Article	IF	CITATIONS
235	Glucan rich nutrition does not increase gut translocation of betaâ€glucan. Mycoses, 2021, 64, 24-29.	1.8	18
236	Relationship of CSF leukocytosis to compartmentalized changes in MCP-1/CCL2 in the CSF of HIV-infected patients undergoing interruption of antiretroviral therapy. Journal of Neuroimmunology, 2006, 179, 180-185.	1.1	17
237	Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 326-334.	0.8	17
238	Self-Predictions of Prospective Memory in HIV-Associated Neurocognitive Disorders: Evidence of a Metamemory Deficit. Archives of Clinical Neuropsychology, 2014, 29, 818-827.	0.3	17
239	HIV Distal Neuropathic Pain Is Associated with Smaller Ventral Posterior Cingulate Cortex. Pain Medicine, 2017, 18, pnw180.	0.9	17
240	Dynamic of CSF and serum biomarkers in HIV-1 subtype C encephalitis with CNS genetic compartmentalizationâ€"case study. Journal of NeuroVirology, 2017, 23, 460-473.	1.0	17
241	Neurocognitive impairment with hepatitis C and HIV co-infection in Southern Brazil. Journal of NeuroVirology, 2018, 24, 339-349.	1.0	17
242	Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C. Journal of NeuroVirology, 2018, 24, 28-40.	1.0	17
243	Cannabis and Inflammation in HIV: A Review of Human and Animal Studies. Viruses, 2021, 13, 1521.	1.5	17
244	Markers of Gut Barrier Function and Microbial Translocation Associate with Lower Gut Microbial Diversity in People with HIV. Viruses, 2021, 13, 1891.	1.5	17
245	Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology, 2002, 58, 1439-1440.	1.5	16
246	Low CSF Leptin Levels are Associated with Worse Learning and Memory Performance in HIV-infected Men. Journal of NeuroImmune Pharmacology, 2007, 2, 352-358.	2.1	16
247	Quantification of cerebrospinal fluid lactic acid in the differential diagnosis between HIV chronic meningitis and opportunistic meningitis. Clinical Chemistry and Laboratory Medicine, 2011, 49, 891-6.	1.4	16
248	Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. Aids, 2012, 26, 890-893.	1.0	16
249	HIV peripheral neuropathy progression: protection with glucose-lowering drugs?. Journal of NeuroVirology, 2012, 18, 428-433.	1.0	16
250	Personalized Risk Index for Neurocognitive Decline Among People With Well-Controlled HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 48-54.	0.9	16
251	Evaluation of the Aptima HIV-1 Quant Dx Assay for HIV-1 RNA Quantitation in Different Biological Specimen Types. Journal of Clinical Microbiology, 2017, 55, 2544-2553.	1.8	16
252	Peripheral Blood Mitochondrial DNA Copy Number Obtained From Genome-Wide Genotype Data Is Associated With Neurocognitive Impairment in Persons With Chronic HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, e95-e102.	0.9	16

#	Article	IF	CITATIONS
253	Psychosocial Correlates of Frailty Among HIV-Infected and HIV-Uninfected Adults. Behavioral Medicine, 2019, 45, 210-220.	1.0	16
254	Objective and subjective sleep measures are associated with neurocognition in aging adults with and without HIV. Clinical Neuropsychologist, 2022, 36, 1352-1371.	1.5	16
255	Cerebrospinal fluid pleocytosis as a predictive factor for CSF and plasma HIV RNA discordance and escape. Journal of NeuroVirology, 2020, 26, 241-251.	1.0	16
256	Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. Journal of NeuroVirology, 2012, 18, 81-90.	1.0	15
257	Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV,the, 2019, 6, e456-e462.	2.1	15
258	Use of Neuroimaging to Inform Optimal Neurocognitive Criteria for Detecting HIV-Associated Brain Abnormalities. Journal of the International Neuropsychological Society, 2020, 26, 147-162.	1.2	15
259	Sex Differences in the Patterns and Predictors of Cognitive Function in HIV. Frontiers in Neurology, 2020, 11, 551921.	1.1	15
260	Low Neuroactive Steroids Identifies a Biological Subtype of Depression in Adults with Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2021, 223, 1601-1611.	1.9	15
261	Valproic acid does not affect markers of human immunodeficiency virus disease progression. Journal of NeuroVirology, 2006, 12, 403-406.	1.0	14
262	Penetration and Effectiveness of Antiretroviral Therapy in the Central Nervous System. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2009, 8, 169-183.	1.1	14
263	HIV and antiretroviral therapy: Impact on the central nervous system. Progress in Neurobiology, 2010, 91, 185-187.	2.8	14
264	Therapeutic Amprenavir Concentrations in Cerebrospinal Fluid. Antimicrobial Agents and Chemotherapy, 2012, 56, 1985-1989.	1.4	14
265	Characteristics of Motor Dysfunction in Longstanding Human Immunodeficiency Virus. Clinical Infectious Diseases, 2020, 71, 1532-1538.	2.9	14
266	Low CD4+ cell count nadir exacerbates the impacts of APOE $\hat{l}\mu4$ on functional connectivity and memory in adults with HIV. Aids, 2021, 35, 727-736.	1.0	14
267	Chronically elevated depressive symptoms interact with acute increases in inflammation to predict worse neurocognition among people with HIV. Journal of NeuroVirology, 2021, 27, 160-167.	1.0	14
268	Aseptic meningitis as a complication of intravenous immunoglobulin therapy for myasthenia gravis. Muscle and Nerve, 1994, 17, 683-684.	1.0	13
269	Meeting Practical Challenges of a Trial Involving a Multitude of Treatment Regimens: An Example of a Multi-Center Randomized Controlled Clinical Trial in NeuroAlDS. Journal of NeuroImmune Pharmacology, 2007, 2, 97-104.	2.1	13
270	Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection. Journal of NeuroVirology, 2008, 14, 550-557.	1.0	13

#	Article	IF	Citations
271	Molecular epidemiology of HIV-1 clades in Southern Brazil. Memorias Do Instituto Oswaldo Cruz, 2010, 105, 1044-1049.	0.8	13
272	Apolipoprotein E $\hat{l}\mu4$ genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals. Journal of NeuroVirology, 2016, 22, 607-614.	1.0	13
273	Human Immunodeficiency Virus–1 RNA Levels in Cerebrospinal Fluid Exhibit a Set Point in Clinically Stable Patients Not Receiving Antiretroviral Therapy. Journal of Infectious Diseases, 2003, 187, 1818-1821.	1.9	12
274	Alterations in the Levels of Vesicular Trafficking Proteins Involved in HIV Replication in the Brains and CSF of Patients with HIV-associated Neurocognitive Disorders. Journal of NeuroImmune Pharmacology, 2013, 8, 1197-1209.	2.1	12
275	Chronic Distal Sensory Polyneuropathy Is a Major Contributor to Balance Disturbances in Persons Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 568-573.	0.9	12
276	Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV. Annals of Clinical and Translational Neurology, 2020, 7, 1166-1173.	1.7	12
277	HIV-1C and HIV-1B Tat protein polymorphism in Southern Brazil. Journal of NeuroVirology, 2021, 27, 126-136.	1.0	12
278	Effects of HIV-1 infection and aging on neurobehavioral functioning. Aids, 2004, , 27-34.	1.0	12
279	Impact of long-term treatment with neurotoxic dideoxynucleoside antiretrovirals: implications for clinical care in resource-limited settings. HIV Medicine, 2008, 9, 731-737.	1.0	11
280	Clinical variables identify seronegative HCV co-infection in HIV-infected individuals. Journal of Clinical Virology, 2011, 52, 328-332.	1.6	11
281	Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. Virology, 2012, 433, 498-505.	1.1	11
282	Brain morphometric correlates of metabolic variables in HIV: the CHARTER study. Journal of NeuroVirology, 2014, 20, 603-611.	1.0	11
283	The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. Psychiatry Research, 2014, 218, 201-208.	1.7	11
284	Elevated Markers of Vascular Remodeling and Arterial Stiffness Are Associated With Neurocognitive Function in Older HIV+ Adults on Suppressive Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 134-141.	0.9	11
285	Pre-frailty predicts cognitive decline at 2-year follow-up in persons living with HIV. Journal of NeuroVirology, 2020, 26, 168-180.	1.0	11
286	Baseline 10-Year Cardiovascular Risk Scores Predict Cognitive Function in Older Persons, and Particularly Women, Living With Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2020, 71, 3079-3085.	2.9	11
287	Alterations of Brain Metabolites in Adults With HIV. Neurology, 2021, 97, e1085-e1096.	1.5	11
288	Toward Composite Pain Biomarkers of Neuropathic Painâ€"Focus on Peripheral Neuropathic Pain. Frontiers in Pain Research, 2022, 3, .	0.9	11

#	Article	IF	Citations
289	Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance. Virology, 2009, 394, 243-248.	1.1	10
290	A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain. Cannabis and Cannabinoid Research, 2019, 4, 62-72.	1.5	10
291	Extrapyramidal motor signs in older adults with HIV disease: frequency, 1-year course, and associations with activities of daily living and quality of life. Journal of NeuroVirology, 2019, 25, 162-173.	1.0	10
292	Incident major depressive episodes increase the severity and risk of apathy in HIV infection. Journal of Affective Disorders, 2015, 175, 475-480.	2.0	9
293	Suicide risk and prevalence of major depressive disorder (MDD) among individuals infected with HIV-1 subtype C versus B in Southern Brazil. Journal of NeuroVirology, 2016, 22, 789-798.	1.0	9
294	Complement Component 3 Is Associated with Metabolic Comorbidities in Older HIV-Positive Adults. AIDS Research and Human Retroviruses, 2016, 32, 271-278.	0.5	9
295	Physical Activity Is Associated With Lower Odds of Cognitive Impairment in Women but Not Men Living With Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2019, 219, 264-274.	1.9	9
296	Blood amyloid-β protein isoforms are affected by HIV-1 in a subtype-dependent pattern. Journal of NeuroVirology, 2020, 26, 3-13.	1.0	9
297	Depression in Individuals Coinfected with HIV and HCV Is Associated with Systematic Differences in the Gut Microbiome and Metabolome. MSystems, 2020, 5, .	1.7	9
298	Depression is associated with hippocampal volume loss in adults with HIV. Human Brain Mapping, 2021, 42, 3750-3759.	1.9	9
299	Prevention of HIV-1 TAT Protein-Induced Peripheral Neuropathy and Mitochondrial Disruption by the Antimuscarinic Pirenzepine. Frontiers in Neurology, 2021, 12, 663373.	1.1	9
300	Reduced Gut Microbiome Diversity in People With HIV Who Have Distal Neuropathic Pain. Journal of Pain, 2022, 23, 318-325.	0.7	9
301	Brain Abscess following Rituximab Infusion in a Patient with Pemphigus Vulgaris. American Journal of Case Reports, 2015, 16, 65-68.	0.3	9
302	Higher cerebrospinal fluid biomarkers of neuronal injury in HIV-associated neurocognitive impairment. Journal of NeuroVirology, 2022, 28, 438-445.	1.0	9
303	Update and New Directions in Therapeutics for Neurological Complications of HIV Infections. Neurotherapeutics, 2016, 13, 471-476.	2.1	8
304	Brief Report: Body Mass Index and Cognitive Function Among HIV-1–Infected Individuals in China, India, and Nigeria. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, e30-e35.	0.9	8
305	COMT Val158Met Polymorphism, Cardiometabolic Risk, and Nadir CD4 Synergistically Increase Risk of Neurocognitive Impairment in Men Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, e148-e157.	0.9	8
306	Catechol-O-methyltransferase polymorphism Vall 58Met is associated with distal neuropathic pain in HIV-associated sensory neuropathy. Aids, 2019, 33, 1575-1582.	1.0	8

#	Article	IF	CITATIONS
307	Risk of developing cerebral \hat{l}^2 -amyloid plaques with posttranslational modification among HIV-infected adults. Aids, 2019, 33, 2157-2166.	1.0	8
308	Cannabis and the Gut–Brain Axis Communication in HIV Infection. Cannabis and Cannabinoid Research, 2021, 6, 92-104.	1.5	8
309	Baseline Neurocognitive Impairment (NCI) Is Associated With Incident Frailty but Baseline Frailty Does Not Predict Incident NCI in Older Persons With Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 2021, 73, 680-688.	2.9	8
310	Low-Level HIV RNA in Cerebrospinal Fluid and Neurocognitive Performance: A Longitudinal Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 1196-1204.	0.9	8
311	Script Generation of Activities of Daily Living in HIV-Associated Neurocognitive Disorders. Journal of the International Neuropsychological Society, 2011, 17, 740-745.	1.2	7
312	Evidence for a novel subcortical mechanism for posterior cingulate cortex atrophy in HIV peripheral neuropathy. Journal of NeuroVirology, 2020, 26, 530-543.	1.0	7
313	Cerebrospinal Fluid Norepinephrine and Neurocognition in HIV and Methamphetamine Dependence. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, e12-e22.	0.9	7
314	Lifetime Methamphetamine Use Disorder and Reported Sleep Quality in Adults Living with HIV. AIDS and Behavior, 2020, 24, 3071-3082.	1.4	7
315	Connectome-based prediction of global cognitive performance in people with HIV. NeuroImage: Clinical, 2021, 30, 102677.	1.4	7
316	lgG intrathecal synthesis in HIV-associated neurocognitive disorder (HAND) according to the HIV-1 subtypes and pattern of HIV RNA in CNS and plasma compartments. Journal of Neuroimmunology, 2021, 355, 577542.	1.1	7
317	European Mitochondrial DNA Haplogroups are Associated with Cerebrospinal Fluid Biomarkers of Inflammation in HIV Infection. Pathogens and Immunity, 2016, 1, 330.	1.4	7
318	The impact of HIV-related neuropsychological dysfunction on driving behavior. Journal of the International Neuropsychological Society, 2000, 6, 854-854.	1.2	6
319	Cognitive changes in asymptomatic drug-na \tilde{A} -ve human immunodeficiency virus type 1 clade C infection. Journal of NeuroVirology, 2008, 14, 480-485.	1.0	6
320	Fibroblast growth factors 1 and 2 in cerebrospinal fluid are associated with HIV disease, methamphetamine use, and neurocognitive functioning. HIV/AIDS - Research and Palliative Care, 2016, 8, 93.	0.4	6
321	Higher Cystatin C Levels Are Associated With Neurocognitive Impairment in Older HIV+ Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 243-249.	0.9	6
322	Transient and asymptomatic meningitis in human immunodeficiency virus-1 subtype C: a case study of genetic compartmentalization and biomarker dynamics. Journal of NeuroVirology, 2018, 24, 786-796.	1.0	6
323	Gait Speed Decline Is Associated with Hemoglobin A1C, Neurocognitive Impairment, and Black Race in Persons with HIV. AIDS Research and Human Retroviruses, 2019, 35, 1065-1073.	0.5	6
324	COMT vall58met genotype alters the effects of methamphetamine dependence on dopamine and dopamine-related executive function: preliminary findings. Psychiatry Research, 2020, 292, 113269.	1.7	6

#	Article	IF	CITATIONS
325	Nucleic acid oxidation is associated with biomarkers of neurodegeneration in CSF in people with HIV. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	6
326	Plasma Citrate and Succinate Are Associated With Neurocognitive Impairment in Older People With HIV. Clinical Infectious Diseases, 2021, 73, e765-e772.	2.9	6
327	Higher Comorbidity Burden Predicts Worsening Neurocognitive Trajectories in People with Human Immunodeficiency Virus. Clinical Infectious Diseases, 2022, 74, 1323-1328.	2.9	6
328	NeuroAIDS in Brazil. Journal of NeuroVirology, 2007, 13, 89-96.	1.0	5
329	Changes in PINCH levels in the CSF of HIV+ individuals correlate with hpTau and CD4 count. Journal of NeuroVirology, 2014, 20, 371-379.	1.0	5
330	Neprilysin in the Cerebrospinal Fluid and Serum of Patients Infected With HIV1-Subtypes C and B. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 248-256.	0.9	5
331	Iron-regulatory genes are associated with Neuroimaging measures in HIV infection. Brain Imaging and Behavior, 2020, 14, 2037-2049.	1.1	5
332	HIV RNA Rebound in Seminal Plasma after Antiretroviral Treatment Interruption. Journal of Virology, 2020, 94, .	1.5	5
333	Detection of H3K4me3 Identifies NeuroHIV Signatures, Genomic Effects of Methamphetamine and Addiction Pathways in Postmortem HIV+ Brain Specimens that Are Not Amenable to Transcriptome Analysis. Viruses, 2021, 13, 544.	1.5	5
334	Large Mitochondrial DNA Deletions in HIV Sensory Neuropathy. Neurology, 2021, 97, e156-e165.	1.5	5
335	CSF markers of AD-related pathology relate specifically to memory impairment in older people with HIV: a pilot study. Journal of NeuroVirology, 2022, 28, 162-167.	1.0	5
336	Cerebrospinal fluid can be used for HIV genotyping when it fails in blood. Arquivos De Neuro-Psiquiatria, 2014, 72, 506-509.	0.3	4
337	Cerebrospinal fluid CXCL10 is associated with the presence of low level CSF HIV during suppressive antiretroviral therapy. Journal of Neuroimmunology, 2021, 353, 577493.	1.1	4
338	Characterization of HIV-Associated Neurocognitive Impairment in Middle-Aged and Older Persons With HIV in Lima, Peru. Frontiers in Neurology, 2021, 12, 629257.	1.1	4
339	Polygenic networks in peripheral leukocytes indicate patterns associated with HIV infection and context-dependent effects of cannabis use. Brain, Behavior, & Immunity - Health, 2022, 20, 100414.	1.3	4
340	Evidence-Based Treatment for HIV-Associated Dementia and Cognitive Impairment: Why So Little. PLOS Clinical Trials, 2007, 2, e15.	3.5	3
341	Association of HIV serostatus and metabolic syndrome with neurobehavioral disturbances. Journal of NeuroVirology, 2020, 26, 888-898.	1.0	3
342	Paresthesia Predicts Increased Risk of Distal Neuropathic Pain in Older People with HIV-Associated Sensory Polyneuropathy. Pain Medicine, 2021, 22, 1850-1856.	0.9	3

#	Article	IF	Citations
343	Association of painful human immunodeficiency virus distal sensory polyneuropathy with aberrant expectation of pain relief: functional magnetic resonance imaging evidence. Brain Communications, 2021, 3, fcab260.	1.5	3
344	Higher Cerebrospinal Fluid Soluble Urokinase-type Plasminogen Activator Receptor, But Not Interferon \hat{I}^3 -inducible Protein 10, Correlate With Higher Working Memory Deficits. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 90, 106-114.	0.9	3
345	The impacts of HIV infection, age, and education on functional brain networks in adults with HIV. Journal of NeuroVirology, 2022, 28, 265-273.	1.0	3
346	Ethnic/Racial Disparities in Longitudinal Neurocognitive Decline in People With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 90, 97-105.	0.9	3
347	Main lymphocyte subpopulations in cerebrospinal fluid and peripheral blood in HIV-1 subtypes C and B. Journal of NeuroVirology, 2022, 28, 291-304.	1.0	3
348	Higher buccal mitochondrial DNA and mitochondrial common deletion number are associated with markers of neurodegeneration and inflammation in cerebrospinal fluid. Journal of NeuroVirology, 2022, 28, 281-290.	1.0	3
349	Soluble CD14 is subtype-dependent in serum but not in cerebrospinal fluid in people with HIV. Journal of Neuroimmunology, 2022, 366, 577845.	1.1	3
350	Clinical Trials in HIV CNS Disease and Treatment Management. Journal of NeuroImmune Pharmacology, 2007, 2, 20-25.	2.1	2
351	Acute HIV infection presenting as fulminant meningoencephalitis with massive CSF viral replication. Neurology: Clinical Practice, 2014, 4, 256-259.	0.8	2
352	Comparison of bead array and glass nanoreactor multi-analyte platforms for the evaluation of CNS and peripheral inflammatory markers during HIV infection. Journal of Immunological Methods, 2019, 465, 7-12.	0.6	2
353	Mitochondrial DNA haplogroups and domain-specific neurocognitive performance in adults with HIV. Journal of NeuroVirology, 2021, 27, 557-567.	1.0	2
354	Higher CSF Ferritin Heavy-Chain (Fth1) and Transferrin Predict Better Neurocognitive Performance in People with HIV. Molecular Neurobiology, 2021, 58, 4842-4855.	1.9	2
355	Memantine for AIDS Dementia Complex: Open-Label Report of ACTG 301. HIV Clinical Trials, 2010, 11, 59-67.	2.0	2
356	Frailty Syndrome Is Associated with Poorer Self-Reported Sleep Quality Among Older Persons with Human Immunodeficiency Virus. AIDS Research and Human Retroviruses, 2022, 38, 87-96.	0.5	2
357	Polypharmacy in older adults with HIV infection: Effects on the brain. Journal of the American Geriatrics Society, 2022, 70, 924-927.	1.3	2
358	Peripheral inflammation and depressed mood independently predict neurocognitive worsening over 12 years. Brain, Behavior, & Immunity - Health, 2022, 21, 100437.	1.3	2
359	Portable lactate analyzer for measuring lactate in cerebrospinal fluid (CSF) and plasma? method-comparison evaluations. Arquivos De Neuro-Psiquiatria, 2014, 72, 500-505.	0.3	1
360	Better executive function is independently associated with full HIV suppression during combination therapy. Aids, 2019, 33, 2309-2316.	1.0	1

#	Article	IF	CITATIONS
361	Neurocytoskeleton Proteins in Cerebrospinal Fluid of People With HIV-1 Subtypes B and C. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 514-521.	0.9	1
362	Reduced Independence in Daily Living Is Associated with the Gut Microbiome in People with HIV and HCV. MSystems, 2020, 5 , .	1.7	1
363	The Effects of Lowâ€Risk Drinking on Neurocognition Among Older Persons Living With HIV as Compared to Those Without HIV. Alcoholism: Clinical and Experimental Research, 2020, 44, 1389-1399.	1.4	1
364	Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV and Aging Workshop. AIDS Research and Human Retroviruses, 2021, 37, 807-820.	0.5	1
365	Neuropathic pain correlates with worsening cognition in people with human immunodeficiency virus. Brain, 2022, 145, 2206-2213.	3.7	1
366	Cognitive and Physiologic Reserve Independently Relate to Superior Neurocognitive Abilities in Adults Aging With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 90, 440-448.	0.9	1
367	A Haptoglobin Exon Copy Number Variant Associates With HIV-Associated Neurocognitive Impairment in European and African-Descent Populations. Frontiers in Genetics, 2021, 12, 756685.	1.1	1
368	Identification of Youthful Neurocognitive Trajectories in Adults Aging with HIV: A Latent Growth Mixture Model. AIDS and Behavior, 2021 , , 1 .	1.4	1
369	Better Biomarkers Are Needed to Improve the Management of the Neurologic Complications of HIV Infection. Clinical Infectious Diseases, 2008, 46, 1940-1941.	2.9	0
370	Reply to Haddow, et al Clinical Infectious Diseases, 2015, 60, 1442-3.	2.9	0
371	Clinical Reasoning: A 22-year-old postpartum woman with new-onset seizures and headache. Neurology, 2018, 90, e1631-e1635.	1.5	0
372	Cannabis use is not associated with increased balance disturbances in HIV-infected individuals. Journal of Cannabis Research, 2021, 3, 3.	1.5	0
373	Viral Dynamics., 2011,, 847-855.		0
374	HIV Neurocognitive Diagnosis, Natural History, and Treatment. , 2015, , 1-11.		0
375	HIV Neurocognitive Diagnosis, Natural History, and Treatment. , 2018, , 730-740.		O
376	Fatigue is associated with worse cognitive and everyday functioning in older persons with HIV. Aids, 2022, 36, 763-772.	1.0	0
377	Prior Methamphetamine Use Disorder History Does Not Impair Interoceptive Processing of Soft Touch in HIV Infection. Viruses, 2021, 13, 2476.	1.5	0
378	Association Between VACS Index and Health-Related Quality of Life in Persons with HIV: Moderating Role of Fruit and Vegetable Consumption. International Journal of Behavioral Medicine, 2022, , 1.	0.8	0

#	Article	IF	CITATIONS
379	Cingulate transcranial direct current stimulation in adults with HIV. PLoS ONE, 2022, 17, e0269491.	1.1	O